

Brompton Global Healthcare Income & Growth ETF
Summary of Investment Portfolio as at March 31, 2022

Total Net Asset Value \$ 72,998,498

Portfolio Composition	% of Net Asset Value
Europe	
Denmark	
Pharmaceuticals	4.9%
Germany	
Pharmaceuticals	5.5%
Healthcare Equipment	1.7%
Great Britain	
Pharmaceuticals	6.9%
Ireland	
Healthcare Equipment	4.4%
Switzerland	
Healthcare Equipment	5.2%
Total Europe	28.6%
North America	
United States	
Healthcare Equipment	20.0%
Pharmaceuticals	17.3%
Life Sciences Tools and Services	7.8%
Managed Healthcare	7.3%
Healthcare Supplies	5.5%
Healthcare Services	5.0%
Biotechnology	4.4%
Healthcare Facilities	2.1%
Total North America	69.4%
Cash & short-term inv.	0.5%
Other net assets	1.5%
Total Net Asset Value	100.0%

Top 25 Holdings	% of Net Asset Value
Novo Nordisk A/S	4.9%
UnitedHealth Group Inc	4.7%
STERIS plc	4.4%
Abbvie Inc	4.4%
AstraZeneca PLC	4.3%
Merck & Co Inc	4.2%
Thermo Fisher Scientific Inc	4.1%
Edwards Lifesciences Corp	4.0%
Pfizer Inc	4.0%
Intuitive Surgical Inc	3.9%
Johnson & Johnson	3.7%
West Pharmaceutical Services Inc	3.7%
IQVIA Holdings Inc	3.7%
IDEXX Laboratories Inc	3.5%
Abbott Laboratories	3.4%
Merck KGaA	3.4%
Zoetis Inc	3.3%
Straumann Holding AG	3.3%
Laboratory Corporation of America Holdings	3.0%
Humana Inc	2.6%
GlaxoSmithKline PLC	2.6%
Danaher Corp	2.2%
Bristol-Myers Squibb Co	2.1%
Bayer AG	2.1%
HCA Healthcare Inc	2.1%
Total	87.6%

The investment portfolio may change due to ongoing portfolio transactions of the investment fund. Quarterly updates are available on the Fund's website at www.bromptongroup.com within 60 days of each quarter end.